Enrolling By InvitationNCT07161700
This study is enrolling by invitation in the United States, in Bulgaria, in Czech Republic, .... It is testing SPT-300 (GlyphAllo) for depression.
DepressionOtherFrom 18 Years to 66 Years
- Countries
- United States, Bulgaria, Czech Republic, ...
- Sponsor
- Seaport Therapeutics
- Condition
- Depression
CompletedNCT00161044
This study is completed in the United States. It focuses on schizophrenia.
SchizophreniaOtherFrom 18 Years to 60 Years
- Countries
- United States
- Sponsor
- University of Maryland, Baltimore
- Condition
- Schizophrenia
CompletedEUCTR 2015-003578-34
This study is completed in the United Kingdom, in Belgium, in Germany, .... It is testing intranasal Esketamine for depression.
DepressionOther
- Countries
- United Kingdom, Belgium, Germany, ...
- Sponsor
- Janssen-Cilag International NV
- Condition
- Depression
Enrolling By InvitationNCT07217860
This study is enrolling by invitation in the United States. It is testing azetukalner for depression.
Bipolarity, DepressionOtherFrom 18 Years to 75 Years
- Countries
- United States
- Sponsor
- Xenon Pharmaceuticals Inc.
- Condition
- Bipolarity, Depression
Enrolling By InvitationNCT06922110
This study is enrolling by invitation in the United States. It is testing azetukalner for depression.
DepressionOtherOver 18 Years
- Countries
- United States
- Sponsor
- Xenon Pharmaceuticals Inc.
- Condition
- Depression
CompletedNCT01873729
This study is completed in the United States. It is testing naltrexone for ADHD.
ADHDOtherFrom 18 Years to 55 Years
- Countries
- United States
- Sponsor
- Massachusetts General Hospital
- Condition
- ADHD
CompletedNCT04820309
This study is completed in the United States. It is testing Long-term Safety, Tolerability, and Efficacy of KarXT for schizophrenia.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- United States
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Condition
- Schizophrenia
TerminatedNCT05643170
This study has public registry information in the United States. It is testing Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT for schizophrenia.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- United States
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Condition
- Schizophrenia
WithdrawnNCT04157062
This study has public registry information in Global. It focuses on Mental health.
Mental healthOtherFrom 18 Years to 60 Years
- Countries
- Global
- Sponsor
- West Virginia University
- Condition
- Mental health
CompletedNCT06315283
This study is completed in the United States, in the United Kingdom, in Croatia, .... It focuses on schizophrenia.
SchizophreniaOtherFrom 18 Years to 64 Years
- Countries
- United States, United Kingdom, Croatia, ...
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
- Condition
- Schizophrenia
OngoingEUCTR 2022-000430-42
This study is ongoing in France, in Belgium, in Sweden, .... It is testing aticaprant for depression.
DepressionOther
- Countries
- France, Belgium, Sweden, ...
- Sponsor
- Janssen-Cilag International NV
- Condition
- Depression
OngoingEUCTR 2021-000805-26
This study is ongoing in Norway. It is testing Manualized MDMA-Assisted Psychotherapy for depression.
DepressionOther
- Countries
- Norway
- Sponsor
- Østfold Hospital Trust
- Condition
- Depression
